Figure 2. TRIP12 Accumulates in Sporadic PD Patients and in PD Mouse Models.
(A) Western blot analysis of TRIP12, GCase, TH, and α-syn protein levels in the SNpc of human PD postmortem brain.
(B) Data in A shown as bar graphs (n=6, each group).
(C) Correlation between TRIP12 and GCase expression (n=6, each group).
(D) GCase activity was measured by inactivating GBA2 protein with CBE treatment in PD postmortem brain and represented in a bar graph (n=6, each group).
(E) GBA1 mRNA levels (n=6, each group).
(F) Western blot analysis of TRIP12, GCase, TH, and α-syn from the VMB of α-syn PFFs-injected mice at 6-months post-injection.
(G) Data in F shown as bar graphs (n=6, each group).
(H) Correlation between TRIP12 and GCase expression (n=6, each group).
(I and J) GCase activity and GBA1 mRNA levels (n=6, each group).
(K) Western blot analysis of TRIP12, GCase, and α-syn from the brainstem region of 9 to 10-month-old human A53T α-syn transgenic mice (hA53T-Tg) or age-matched nontransgenic mice (non-Tg).
(L) Data in K shown as bar graphs (n=6, each group).
(M) Correlation between TRIP12 and GCase expression (n=6, each group).
(N and O) GCase activity and GBA1 mRNA levels. Data are presented as mean ± SEM (NS; not significant, *P < 0.05, **P < 0.01, ***P < 0.001).